NUVECTIS PHARMA INC. - COMMON STOCK

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

25 сен 2023 18:30:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

21 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial

12 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

06 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

01 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

17 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

09 авг 2023 07:00:58 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes

20 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

15 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

10 май 2023 07:00:02 Источник Nasdaq GlobeNewswire

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

27 апр 2023 09:14:23 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

27 апр 2023 07:00:02 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting

18 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

10 апр 2023 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

17 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

10 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

07 мар 2023 07:00:31 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress

23 фев 2023 07:00:02 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®

09 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

04 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire